A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use

BACKGROUND:The worst outcome of gastrointestinal complications is death. Data regarding those associated with nonsteroidal antiinflammatory drug (NSAID) or aspirin use are scarce.AIM:To determine mortality associated with hospital admission due to major gastrointestinal (GI) events and NSAID/aspirin use.METHODS:The study was based on actual count of deaths from two different data sets from 2001. Study 1 was carried out in 26 general hospitals serving 7,901,198 people. Study 2 used a database from 197 general hospitals, representative of the 269 hospitals in the Spanish National Health System. Information regarding gastrointestinal complications and deaths was obtained throughout the Minimum Basic Data Set (CIE-9-MC) provided by participating hospitals. Deaths attributed to NSAID/aspirin use were estimated on the basis of prospectively collected data from hospitals of study 1.RESULTS:The incidence of hospital admission due to major GI events of the entire (upper and lower) gastrointestinal tract was 121.9 events/100,000 persons/year, but those related to the upper GI tract were six times more frequent. Mortality rate was 5.57% (95% CI = 4.9–6.7), and 5.62% (95% CI = 4.8–6.8) in study 1 and study 2, respectively. Death rate attributed to NSAID/aspirin use was between 21.0 and 24.8 cases/million people, respectively, or 15.3 deaths/100,000 NSAID/aspirin users. Up to one-third of all NSAID/aspirin deaths can be attributed to low-dose aspirin use.CONCLUSION:Mortality rates associated with either major upper or lower GI events are similar but upper GI events were more frequent. Deaths attributed to NSAID/ASA use were high but previous reports may have provided an overestimate and one-third of them can be due to low-dose aspirin use.

[1]  C. Wilcox,et al.  Nonsteroidal Antiinflammatory Drugs Are Associated with Both Upper and Lower Gastrointestinal Bleeding , 1997, Digestive Diseases and Sciences.

[2]  J. Reitsma,et al.  Acute upper GI bleeding: did anything change? , 2003, American Journal of Gastroenterology.

[3]  D. Martos,et al.  Comparabilidad entre la novena y la décima revisión de la Clasificación Internacional de Enfermedades aplicada a la codificación de la causa de muerte en España , 2002 .

[4]  Á. Lanas,et al.  Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection , 2005, Alimentary pharmacology & therapeutics.

[5]  W. Bilker,et al.  Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications , 2002, American Journal of Gastroenterology.

[6]  G. Triadafilopoulos,et al.  Epidemiology of NSAID induced gastrointestinal complications. , 1999, The Journal of rheumatology. Supplement.

[7]  T. Schnitzer,et al.  Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. , 2003, Gastroenterology.

[8]  Lilienfeld Am,et al.  Foundations of epidemiology. 2nd ed. , 1980 .

[9]  J. Tijssen,et al.  Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. , 2003, The American journal of gastroenterology.

[10]  B. Hirschowitz,et al.  CONTROVERSIES IN THE DETECTION AND MANAGEMENT OF NONSTEROIDAL ANTIINFLAMMATORY DRUG‐INDUCED SIDE EFFECTS OF THE UPPER GASTROINTESTINAL TRACT , 1989, Arthritis and rheumatism.

[11]  C. Hawkey,et al.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors , 2003, Gut.

[12]  H. Magee The Hospital Data Project: comparing hospital activity within Europe. , 2003, European journal of public health.

[13]  J. Kurata,et al.  Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. , 1997, Journal of clinical gastroenterology.

[14]  S. Morant,et al.  Emergency admissions for upper gastrointestinal disease and their relation to NSAID use , 1997, Alimentary pharmacology & therapeutics.

[15]  M. Kimmey,et al.  Appropriate use of proton pump inhibitors with traditional nonsteroidal anti‐inflammatory drugs and COX‐2 selective inhibitors , 2004, Alimentary pharmacology & therapeutics.

[16]  A. Jiménez-Puente,et al.  Valoración diagnóstica clínica y analítica de la trombosis venosa profunda de miembros inferiores , 2000 .

[17]  A. Lilienfeld Foundations of Epidemiology , 1980 .

[18]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[19]  W. Straus,et al.  Gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs. Epidemiologic and economic issues. , 2001, Gastroenterology clinics of North America.

[20]  R. Moore The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy. , 2002, Rheumatology.

[21]  A. Majeed,et al.  Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects , 2002, Gut.

[22]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[23]  Á. Lanas,et al.  CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate , 2003 .

[24]  M. Tramèr,et al.  Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use , 2000, Pain.

[25]  J. Senior,et al.  Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs , 1995, Annals of Internal Medicine.

[26]  H B Devlin,et al.  Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom , 1995 .

[27]  G. Harewood Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.

[28]  H B Devlin,et al.  Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. , 1995, BMJ.

[29]  Hirschowitz Bi,et al.  Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. , 1989 .

[30]  M. Langman,et al.  Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. , 1985, British medical journal.

[31]  J. Gisbert,et al.  Proton pump inhibitors versus H2‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcer , 2001, Alimentary pharmacology & therapeutics.

[32]  Á. Lanas,et al.  Evidence of aspirin use in both upper and lower gastrointestinal perforation. , 1997, Gastroenterology.